Sustained virological response · participants with detectable HCV RNA after 12 weeks of treatment with pegylated interferon and ribavirin, but with >= 2 log viral…
It is very uncertain whether extended peginterferon plus ribavirin treatment for 72 weeks changes sustained virological response (SVR) compared with standard peginterferon plus ribavirin treatment (very low certainty).
1 finding from 1 review
Relapse · participants with detectable HCV RNA after 12 weeks of treatment with pegylated interferon and ribavirin, but with >= 2 log viral…
It is very uncertain whether extended peginterferon plus ribavirin treatment for 72 weeks changes relapse compared with standard peginterferon plus ribavirin treatment (very low certainty).
1 finding from 1 review
End of treatment response (ETR) · participants with detectable HCV RNA after 12 weeks of treatment with pegylated interferon and ribavirin, but with >= 2 log viral…
It is very uncertain whether extended peginterferon plus ribavirin treatment for 72 weeks changes end of treatment response (ETR) compared with standard peginterferon plus ribavirin treatment (very low certainty).
1 finding from 1 review
Sustained virological response · participants with detectable HCV RNA after four weeks of treatment with pegylated interferon and ribavirin
Extended peginterferon plus ribavirin treatment for 72 weeks may leads to higher sustained virological response (SVR) compared with standard peginterferon plus ribavirin treatment (low certainty).
1 finding from 1 review
Relapse · participants with detectable HCV RNA after four weeks of treatment with pegylated interferon and ribavirin
Extended peginterferon plus ribavirin treatment for 72 weeks may leads to lower relapse rate compared with standard peginterferon plus ribavirin treatment (low certainty).
1 finding from 1 review
End of treatment response (ETR) · participants with detectable HCV RNA after four weeks of treatment with pegylated interferon and ribavirin
Extended peginterferon plus ribavirin treatment for 72 weeks may leads to lower end of treatment response (ETR) compared with standard peginterferon plus ribavirin treatment (low certainty).
1 finding from 1 review
Adherance to treatment · participants with detectable HCV RNA after four weeks of treatment with pegylated interferon and ribavirin or participants with detectable…
Extended peginterferon plus ribavirin treatment for 72 weeks probably leads to lower adherance to treatment compared with standard peginterferon plus ribavirin treatment (moderate certainty).
1 finding from 1 review
All‐cause mortality Deaths during and after the treatment · people with chronic hepatitis C
It is very uncertain whether peginterferon alpha‐2a changes all‐cause mortality Deaths during and after the treatment compared with peginterferon alpha‐2b (very low certainty).
1 finding from 1 review
Liver morbidity · people with chronic hepatitis C
It is very uncertain whether peginterferon alpha‐2a changes liver‐related morbidity Number of events compared with peginterferon alpha‐2b (very low certainty).
1 finding from 1 review
Serious adverse events Number of events · people with chronic hepatitis C
Peginterferon alpha‐2a showed no clear difference in serious adverse events Number of events compared with peginterferon alpha‐2b (low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · people with chronic hepatitis C
Peginterferon alpha‐2a showed no clear difference in adverse events leading to treatment discontinuation Number of events compared with peginterferon alpha‐2b (low certainty).
1 finding from 1 review
All other (non‐serious) adverse events · people with chronic hepatitis C
1 finding from 1 review
Quality of life SF 36 and CLDQ · people with chronic hepatitis C
1 finding from 1 review
Sustained virological response · people with chronic hepatitis C
Peginterferon alpha‐2a probably leads to higher sustained virological response Absence of viraemia 24 weeks after… compared with peginterferon alpha‐2b (moderate certainty).
1 finding from 1 review
All‐cause mortality or liver‐related morbidity · people with chronic hepatitis C
Peginterferon plus ribavirin showed no clear difference in liver‐related morbidity plus all‐cause mortality compared with non‐pegylated interferon plus ribavirin (low certainty).
1 finding from 1 review
OR 1.14 [0.38, 3.42]
1789 participants
Low
Discontinuation of medication due to adverse events · people with chronic hepatitis C
Peginterferon plus ribavirin showed no clear difference in adverse events leading to treatment discontinuation compared with non‐pegylated interferon plus ribavirin (low certainty).
1 finding from 1 review
Sustained virological response · people with chronic hepatitis C
It is very uncertain whether peginterferon plus ribavirin changes sustained virological response compared with non‐pegylated interferon plus ribavirin (very low certainty).
1 finding from 1 review
Serious adverse events (number) ‐ pegylated interferon‐alpha plus ribavirin versus pegylated interferon‐alpha · people with acute hepatitis C infection
It is very uncertain whether intervention changes serious adverse events (proportion) ‐ pegylated interferon‐alpha… compared with no intervention or control intervention (control) (very low certainty).
2 findings from 1 review
OR 1.72 [0.7, 4.21]
2 studies · 237 participants
Very low
Rate ratio 2.74 [1.4, 5.33]
2 studies · 237 participants
Very low
Chronic HCV infection†‐ pegylated interferon‐alpha plus ribavirin versus pegylated interferon‐alpha · people with acute hepatitis C infection
It is very uncertain whether intervention changes chronic HCV infection†‐ pegylated interferon‐alpha plus ribavirin… compared with no intervention or control intervention (control) (very low certainty).
1 finding from 1 review
Intervention not reported
Peg interferon vs.control · Participants with recurrent liver graft infection with hepatitis C virus.
It is very uncertain whether the intervention changes peg interferon vs.control (very low certainty).
1 finding from 1 review